Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has ...
It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results